Clinical trials: CGM
Type 1 Diabetes
Safety Evaluation of MiniMed™ 780G System With DS5 CGM in Children
The purpose of this study is to evaluate the safety of the MiniMed 780G insulin pump used in combination with the DS5 CGM in type 1 pediatric subjects (2-6 years of age) in a home setting.
- Trial name
- SUCCEED2 (NCT06604871)
- Testing
- Insulin Pump with Continuous Glucose Monitoring
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Medtronic MiniMed, Inc.
Patients Needing Glucose Control
Effectiveness and Safety of the Dexcom G6 Continuous Glucose Monitoring System in Non-Critically Ill Patients in the Inpatient Setting
Effectiveness and Safety of the Dexcom G6 Continuous Glucose Monitoring System in Non-Critically Ill Patients in the Inpatient Setting
- Trial name
- NCT04879693
- Testing
- Continuous Glucose Monitoring System
- Volunteers
- 250 people
- Sponsor
- DexCom, Inc.
Type 1 Diabetes, Type 2 Diabetes
Feasibility Trial of the Bios Device for Continuous Glucose Monitoring
The study is an open-label, prospective, within-subject comparison of the Bios device readings versus venous blood sample glucose readings, glucose readings from a Dexcom CGM and an SMBG device in subjects previously diagnosed…
- Trial name
- NCT04226846
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- GraphWear Technologies Inc.
Diabetes Mellitus
FreeStyle Libre 3 Continuous Glucose Monitoring System
The purpose of this study is to characterize the FreeStyle Libre 3 Continuous Glucose Monitoring System performance with respect to YSI reference venous plasma sample measurements.
- Trial name
- NCT05962710
- Testing
- FreeStyle Libre 3
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Abbott Diabetes Care
Type 1 Diabetes Mellitus
Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)
The purpose of this pilot study is to evaluate performance of the SEVEN System and the Navigator System when both devices are worn concurrently by subjects with type 1 diabetes mellitus.
- Trial name
- NCT00939289
- Testing
- Continuous Glucose Monitoring
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- DexCom, Inc.
Diabetes Mellitus Type 2
Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement
Primary objective: Difference in frequency of subjects with conventionally detected hypoglycemia by the subject [at least one measurement smaller/equal 60mg/dl documented in the 8-point profile in the case record form (CRF) or…
- Trial name
- SAFIR (NCT00354939)
- Testing
- Insulin glargine
- Volunteers
- 480 people
- Sponsor
- Sanofi
Type 1 Diabetes
Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study
Subjects will use the Omnipod Horizon™ System in Manual Mode in an outpatient setting for 14-days. Subjects will be trained to use the Manual Mode feature of the Omnipod Horizon™ System including how to use the bolus calculator…
- Trial name
- NCT04320069
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Insulet Corporation
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1D) or insulin-dependent Type 2 diabetes (T2D) on a multiple daily injection (MDI) regime.
- Trial name
- NCT06704672
- Testing
- Accu-Chek SmartGuide CGM Solution, Accu-Chek SmartGuide Sensor and Blinded Apps, SMBG Device
- Where
- 20 sites in Poland, Turkey (Türkiye)
- Volunteers
- 270 people
- Sponsor
- Hoffmann-La Roche
Healthy, Type 2 Diabetes Mellitus
Type 2 Diabetes Glucose Biomarker Study With a Continuous Glucose Monitoring System
Current gold standard methodologies for diagnosing type 2 diabetes (T2D) or prediabetes can be unreliable and inaccurate, and require the need for multiple different tests for comparison.
- Trial name
- NCT04529239
- Testing
- Abbott Freestyle Libre Pro
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Klick Inc.
Diabetes Mellitus Type 1
A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections
This study will be conducted in subjects with Type 1 diabetes mellitus on multiple daily insulin injections to determine the correct insulin dosing formulas. Subjects will be evaluated using continuous glucose monitoring.
- Trial name
- NCT01045954
- Testing
- Lispro Insulin and glargine insulin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Diabetes Care Center
Diabetes (DM)
A Study to Investigate a Transdermal Continuous Glucose Monitoring System in Diabetic Patients for a Period of 28 Days
Single-centre, open label (unblinded). A maximum of 48 patients will be enrolled in 4 Cohorts of 10 patients and 2 potential replacements each. Diabetic patients (type 1 and 2).
- Trial name
- FiberSense (NCT06868043)
- Testing
- FiberSense System
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- EyeSense GmbH
Diabetes Mellitus, Type 1
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a…
- Trial name
- NCT05904743
- Testing
- Afrezza, insulin degludec, Rapid-acting Insulin Analog
- Where
- 19 sites in United States
- Volunteers
- 141 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus
Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System
Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System
- Trial name
- NCT04645641
- Testing
- Continuous Glucose Monitoring System
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- DexCom, Inc.
Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
A 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase, will be conducted to assess the safety of MODI, an insulin titration algorithm, in adults with type 1 diabetes (T1D) who use multiple daily…
- Trial name
- MODIUS (NCT07599982)
- Testing
- MODI Algorithm
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- DreaMed Diabetes
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Metronom Continuous Glucose Monitoring System
The aim of the present study is to investigate the clinical performance of the Metronom CGM system in patients with type 1 diabetes over a period of 14 days.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabete Mellitus
- Trial name
- NCT03341026
- Testing
- Metronom CGM device
- Where
- 2 sites in Austria, Denmark
- Volunteers
- 20 people
- Sponsor
- Metronom Health
Diabetes Mellitus, Type 2
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
A Study to assess if patients with Type 2 diabetes (T2D) who have suboptimal glycemic control using multiple oral agents are able to make lifestyle changes resulting in improved glycemic control by use of real-time continuous…
- Trial name
- COMMITED (NCT03620357)
- Testing
- CGM, SMBG
- Where
- 10 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- DexCom, Inc.
Type2 Diabetes
Cardio-metabolic and Inflammatory Impact of Starch Digestibility in Type 2 Diabetic Patients
This is a monocentric, randomized, single-blind and controlled study with a parallel design (2 arms). The research hypothesis is that the diet high in Slow Digestible Starch (SDS) content (H-SDS) will lower the daylong glycemic…
- Trial name
- NCT03847701
- Testing
- Balanced diet high in Slowly Digestible Starch, Balanced diet low in Slowly Digestible Starch
- Where
- France
- Volunteers
- 53 people
- Sponsor
- Mondelēz International, Inc.
Diabetes
Interventional Clinical Trial Evaluating COVER PATCH CAPTEUR PROTECT Support Solutions for Continuous Glucose Monitoring Sensors in Patients With Diabetes
The aim of this clinical trial is to evaluate whether the COVER PATCH adhesive patch can improve the adhesion of continuous glucose monitors (CGMs).
- Trial name
- ICP-COVERPATCH (NCT07018180)
- Testing
- Use of COVER patchs for continuous glucose monitoring sensor
- Where
- 7 sites in France, Guadeloupe
- Volunteers
- 194 people
- Sponsor
- CAPTEUR PROTECT
Healthy
Data Acquisition to Model Glycemic Response
To learn about individual glycemic response to physiological and psychological conditions across a diverse population, the investigators will collect sensor and lifestyle data directly from participants as they engage in daily…
- Trial name
- SDI (NCT03612999)
- Testing
- Dexcom continuous glucose monitor, Fitbit activity tracker, Subjects record daily activity
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Savvysherpa, Inc.
Diabetes Mellitus, Continuous Glucose Monitoring System
To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period
This study is a post-market, prospective, interventional, multicenter clinical trial designed to evaluate the impact of the iCan O3 Continuous Glucose Monitoring (CGM) System on glycemic control in adults with Type 1 (T1D) or…
- Trial name
- DETECT (NCT06904846)
- Testing
- iCan o3 CGM Continuous Glucose Monitoring System
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Sinocare